Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vincent Giacalone

Podiatrist, Foot & Ankle Surgery Emerson, NJ Doctor of Podiatric Medicine

NPI 1285637025 CMS profile 285443

466 Old Hook Rd, Suite 24D, Emerson, NJ 07630

Open in the dashboard

General payments

$73,633

265 records reported · program years 2019–2025

Research payments

$1,592

Paid to them · 8 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$75,137 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Vincent Giacalone of Emerson, NJ is reported in the CMS Open Payments database as having received $73,633 across 265 general payments and $1,592 in research payments paid to them. Separately, studies naming them as principal investigator received $75,137 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,079 71
2025 Research $1,592 8
2024 General $19,422 69
2023 General $11,471 63
2022 General $2,168 28
2021 General $635 17
2020 General $411 8
2019 General $447 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vincent Giacalone
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Vincent Giacalone were reported at $39,079. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Vincent Giacalone Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $447 $389 $118–$1,406 $163
2020 $411 $191 $62–$691 $114
2021 $635 $329 $104–$1,341 $132
2022 $2,168 $419 $125–$1,611 $149
2023 $11,471 $377 $128–$1,164 $160
2024 $19,422 $394 $134–$1,168 $164
2025 $39,079 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Paratek Pharmaceuticals, Inc. $50,125 95 payments
  2. Organogenesis Inc. $15,679 41 payments
  3. Orpyx Medical Technologies Inc. $2,000 1 payment
  4. Smith+Nephew, Inc. $1,384 39 payments
  5. Tactile Systems Technology Inc $661 12 payments
  6. Kerecis Limited $527 4 payments
  7. Integra LifeSciences Corporation $480 11 payments
  8. Stryker Corporation $397 5 payments
  9. Treace Medical Concepts, Inc. $361 7 payments
  10. Urgo Medical North America, LLC $226 4 payments
  11. Other $1,793 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,416 26 payments
  2. Food and Beverage $9,934 208 payments
  3. Travel and Lodging $6,065 28 payments
  4. Consulting Fee $2,000 1 payment
  5. Education $218 2 payments
Products named General payments · program years 2019–2025
  1. NUZYRA $50,125 95 payments
  2. Puraply Antimicrobial $6,343 16 payments
  3. PURAPLY WOUND MATRIX $4,081 5 payments
  4. Affinity $3,598 5 payments
  5. APLIGRAF Wound Care $2,006 4 payments
  6. NuShield $1,979 3 payments
  7. NOVACHOR $1,979 3 payments
  8. Puraply $1,712 11 payments
  9. Apligraf Wound Care $1,625 2 payments
  10. Flexitouch Plus $661 12 payments
  11. Other $11,533 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,592 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

79

Median for Podiatry: 160

Drug cost

$15,785

Median for Podiatry: $2,368

Branded share of claims

62%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 26 $13,125
Cromolyn Sodium Generic 11 $2,129
Nystatin-Triamcinolone Nystatin/Triamcinolone Acet Brand 23 $403
Methylprednisolone Generic 19 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$143,207

Of which drugs: $17,608

Medicare patients

431

Average age 78

Services billed

2,644

233 women, 198 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 51%
Ischemic heart disease 36%
Chronic kidney disease 24%
Atrial fibrillation 22%
Cancer 20%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $12,085
$12,085 — —
KRYSTEXXA
  • Amgen Inc. $135
$135 — —
DALVANCE
  • AbbVie, Inc. $21
$21 — —
TEFLARO
  • AbbVie, Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record